Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 2, 2013, Pages 318-327

  Busnelli, Marta ^a,b   Bulgheroni, Elisabetta ^a   Manning, Maurice ^c   Kleinau, Gunnar ^d   Chini, Bice ^a  

^a CNR   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF TOLEDO   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OXYTOCIN RECEPTOR; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HUMAN; LIGAND BINDING; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHARMACOLOGICAL STIMULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RECEPTOR BINDING; STRUCTURAL HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; ARRESTINS; BRAIN; CERCOPITHECUS AETHIOPS; COS CELLS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HEK293 CELLS; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OXYTOCIN; RADIOLIGAND ASSAY; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP; VASOPRESSINS;

EID: 84880417117     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.202994     Document Type: Article

References (47)

1. Barberis C, Morin D, Durroux T, Mouillac B, Guillon G, Seyer R, Hibert M, and Tribollet E (1999) Molecular pharmacology of AVP and OT receptors and therapeutic potential. Drug News Perspect 12:279-292.
2. Birnbaumer M (2000) Vasopressin receptors. Trends Endocrinol Metab 11:406-410.
3. Busnelli M, Saulière A, Manning M, Bouvier M, Galés C, and Chini B (2012) Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes. J Biol Chem 287:3617-3629.
4. Chini B and Manning M (2007) Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges. Biochem Soc Trans 35:737-741.
5. Chini B, Manning M, and Guillon G (2008) Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an "easy guide" to receptor pharmacology. Prog Brain Res 170:513-517.
6. Chini B, Mouillac B, Ala Y, Balestre MN, Trumpp-Kallmeyer S, Hoflack J, Elands J, Hibert M, Manning M, and Jard S, et al. (1995) Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. EMBO J 14: 2176-2182.
7. Costanzi S (2012) Homology modeling of class A G protein-coupled receptors. Methods Mol Biol 857:259-279.
8. Deupi X and Standfuss J (2011) Structural insights into agonist-induced activation of G-protein-coupled receptors. Curr Opin Struct Biol 21:541-551.
9. Elands J, Barberis C, and Jard S (1988) [3H]-[Thr4,Gly7]OT: a highly selective ligand for central and peripheral OT receptors. Am J Physiol 254:E31-E38.
10. Engelmann M, Wotjak CT, Neumann I, Ludwig M, and Landgraf R (1996) Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Neurosci Biobehav Rev 20:341-358.
11. Ferguson JN, Aldag JM, Insel TR, and Young LJ (2001) Oxytocin in the medial amygdala is essential for social recognition in the mouse. J Neurosci 21:8278-8285.
12. Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, and Winslow JT (2000) Social amnesia in mice lacking the oxytocin gene. Nat Genet 25:284-288.
13. Fernando RN, Larm J, Albiston AL, and Chai SY (2005) Distribution and cellular localization of insulin-regulated aminopeptidase in the rat central nervous system. J Comp Neurol 487:372-390.
14. Galés C, Van Durm JJ, Schaak S, Pontier S, Percherancier Y, Audet M, Paris H, and Bouvier M (2006) Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat Struct Mol Biol 13:778-786.
15. Gozzi A, Jain A, Giovannelli A, Bertollini C, Crestan V, Schwarz AJ, Tsetsenis T, Ragozzino D, Gross CT, and Bifone A (2010) A neural switch for active and passive fear. Neuron 67:656-666.
16. Gravati M, Busnelli M, Bulgheroni E, Reversi A, Spaiardi P, Parenti M, Toselli M, and Chini B (2010) Dual modulation of inward rectifier potassium currents in olfactory neuronal cells by promiscuous G protein coupling of the oxytocin receptor. J Neurochem 114:1424-1435.
17. Hanson MA and Stevens RC (2009) Discovery of new GPCR biology: one receptor structure at a time. Structure 17:8-14.
18. Higashida H, Yokoyama S, Munesue T, Kikuchi M, Minabe Y, and Lopatina O (2011) CD38 gene knockout juvenile mice: a model of oxytocin signal defects in autism. Biol Pharm Bull 34:1369-1372.
19. Huber D, Veinante P, and Stoop R (2005) Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 308:245-248.
20. Jacobson KA and Costanzi S (2012) New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors. Mol Pharmacol 82: 361-371.
21. Jean-Alphonse F, Perkovska S, Frantz MC, Durroux T, Méjean C, Morin D, Loison S, Bonnet D, Hibert M, and Mouillac B, et al. (2009) Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 20:2190-2203.
22. Jin D, Liu HX, Hirai H, Torashima T, Nagai T, Lopatina O, Shnayder NA, Yamada K, Noda M, and Seike T, et al. (2007) CD38 is critical for social behaviour by regulating oxytocin secretion. Nature 446:41-45.
23. Kenakin T (2011) Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336:296-302.
24. Kobilka B and Schertler GF (2008) New G-protein-coupled receptor crystal structures: insights and limitations. Trends Pharmacol Sci 29:79-83.
25. Kratochwil NA, Gatti-McArthur S, Hoener MC, Lindemann L, Christ AD, Green LG, Guba W, Martin RE, Malherbe P, and Porter RH, et al. (2011) G protein-coupled receptor transmembrane binding pockets and their applications in GPCR research and drug discovery: a survey. Curr Top Med Chem 11:1902-1924.
26. Lowbridge J, Manning M, Haldar J, and Sawyer WH (1977) Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3- mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxyl[Thr4, Gly7] oxytocin), and [7-glycine]oxytocin: peptides with high oxytocic-antidiuretic selectivity. J Med Chem 20:120-123.
27. MacKinnon AC, Tufail-Hanif U, Wheatley M, Rossi AG, Haslett C, Seckl M, and Sethi T (2009) Targeting V1A-vasopressin receptors with [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies. Br J Pharmacol 156:36-47.
28. Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M, and Guillon G (2012) Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 24: 609-628.
29. Manning M, Stoev S, Chini B, Durroux T, Mouillac B, and Guillon G (2008) Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res 170:473-512.
30. Michino M, Abola E, Brooks CL, 3rd, Dixon JS, Moult J, and Stevens RC; GPCR Dock 2008 participants (2009) Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nat Rev Drug Discov 8:455-463.
31. Miller G (2013) Neuroscience. The promise and perils of oxytocin. Science 339: 267-269.
32. Modi ME and Young LJ (2012) The oxytocin system in drug discovery for autism: animal models and novel therapeutic strategies. Horm Behav 61:340-350.
33. Oshikawa S, Tanoue A, Koshimizu TA, Kitagawa Y, and Tsujimoto G (2004) Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach. Mol Pharmacol 65:623-629.
34. Pittman QJ and Spencer SJ (2005) Neurohypophysial peptides: gatekeepers in the amygdala. Trends Endocrinol Metab 16:343-344.
35. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, and Calinski D, et al. (2011) Crystal structure of the b2 adrenergic receptor-Gs protein complex. Nature 477:549-555.
36. Reversi A, Rimoldi V, Marrocco T, Cassoni P, Bussolati G, Parenti M, and Chini B (2005) The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism. J Biol Chem 280:16311-16318.
37. Ring RH, Schechter LE, Leonard SK, Dwyer JM, Platt BJ, Graf R, Grauer S, Pulicicchio C, Resnick L, and Rahman Z, et al. (2010) Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 58:69-77.
38. Sala M, Braida D, Donzelli A, Martucci R, Busnelli M, Bulgheroni E, Rubino T, Parolaro D, Nishimori K, and Chini B (2013) Mice heterozygous for the oxytocin receptor gene (Oxtr(1/-)) show impaired social behaviour but not increased aggression or cognitive inflexibility: evidence of a selective haploinsufficiency gene effect. J Neuroendocrinol 25:107-118.
39. Sala M, Braida D, Lentini D, Busnelli M, Bulgheroni E, Capurro V, Finardi A, Donzelli A, Pattini L, and Rubino T, et al. (2011) Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry 69:875-882.
40. Serradeil-Le Gal C, Raufaste D, Derick S, Blankenstein J, Allen J, Pouzet B, Pascal M, Wagnon J, and Ventura MA (2007) Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand. Am J Physiol Regul Integr Comp Physiol 293:R938-R949.
41. Takayanagi Y, Yoshida M, Bielsky IF, Ross HE, Kawamata M, Onaka T, Yanagisawa T, Kimura T, Matzuk MM, and Young LJ, et al. (2005) Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. Proc Natl Acad Sci USA 102:16096-16101.
42. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, and Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
43. Wallis M (2012) Molecular evolution of the neurohypophysial hormone precursors in mammals: comparative genomics reveals novel mammalian oxytocin and vasopressin analogues. Gen Comp Endocrinol 179:313-318.
44. Wesley VJ, Hawtin SR, Howard HC, and Wheatley M (2002) Agonist-specific, highaffinity binding epitopes are contributed by an arginine in the N-terminus of the human oxytocin receptor. Biochemistry 41:5086-5092.
45. Wichard JD, Ter Laak A, Krause G, Heinrich N, Kühne R, and Kleinau G (2011) Chemogenomic analysis of G-protein coupled receptors and their ligands deciphers locks and keys governing diverse aspects of signalling. PLoS ONE 6:e16811.
46. Zhao Q and Wu BL (2012) Ice breaking in GPCR structural biology. Acta Pharmacol Sin 33:324-334.
47. Zingg HH and Laporte SA (2003) The oxytocin receptor. Trends Endocrinol Metab 14: 222-227.